Why Patient Quality of Life Must Be Central in Advanced Cancer Trials – EORTC
European Organisation for Research and Treatment of Cancer (EORTC) shared a post on X:
“New in The Lancet Oncology:
Policy review led by Ian Tannock and Madeline Pe with EORTC and Common Sense Oncology underscores why patient quality of life must be central in advanced cancer trials.
Title: Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer
Authors: Ian F Tannock, Madeline Lee Pe, Christopher M Booth, Michael Brundage, Nathan I Cherny, Corneel Coens, Elizabeth A Eisenhauer, Jan Geissler, Johannes M Giesinger, Bishal Gyawali, Sjoukje F Oosting, Gregory R Pond, Jaap C Reijneveld, Enrique Soto-Perez-de-Celis, Michelle Tregear, Winette T A van der Graaf
Read The Full Article at The Lancet Oncology.
More posts featuring EORTC on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023